Synchrogenix, CISCRP Partner on Lay Summaries of Clinical Trials
Certara®, a global biosimulation technology-enabled drug development consultancy, and CISCRP, an independent nonprofit organization dedicated to educating and informing the public and patients about clinical research, announced that they are partnering to produce high-quality lay summaries of clinical trials.
Certara®, a global biosimulation technology-enabled drug development consultancy, and CISCRP, an independent nonprofit organization dedicated to educating and informing the public and patients about clinical research, announced that they are partnering to produce high-quality lay summaries of clinical trials. Lay summaries are brief descriptions of a clinical trial’s design, objectives and results, and are written for biopharmaceutical companies to share with the general public.
The recently published Institute of Medicine report, “Sharing Clinical Trial Data: Maximizing Benefits, Minimizing Risk,” outlined principles and shared a framework for the responsible sharing of clinical trial data. The tenets outlined in this report, along with EFPIA and PhRMA’s responsible data sharing principles and the new European Medicines Agency Clinical Trial Regulation have resulted in increased focus on clinical trials disclosure. Leading biopharmaceutical companies are now creating Scientific Review Boards to independently assess requests for clinical data and implementing broader clinical trials transparency programs with an emphasis on communications to both the research and lay communities.
Synchrogenix’s medical writers will develop the text and images for each lay summary and implement the company’s quality control processes to ensure data and message accuracy. CISCRP will deliver a critical, unbiased review of the report, engage and interact with investigative sites, and manage production, dissemination and communications of the report.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
